Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis

Vaccine

Volumn 18, Issue 26, 2000, Pages 3005-3010

  Gillis, David ^a,b   Yetiv, Nir ^a   Gdalevich, Michael ^a,c   Mimouni, Daniel ^a   Ashkenazi, Isaac ^a,c   Shpilberg, Ofer ^a   Eldad, Arieh ^a,b   Shemer, Joshua ^c,d  

^a MEDICAL CORPS   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

Hepatitis A; Immune Serum Globulin; Inactivated HAV vaccine

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOGLOBULIN; INACTIVATED VACCINE;

ACTIVE IMMUNIZATION; ARMY; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEPATITIS A; HUMAN; HUMAN EXPERIMENT; IMMUNE STATUS; ISRAEL; MALE; OCCUPATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0034237438     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00091-8     Document Type: Article

References (15)

1. Matzkin H. Acute non-B hepatitis in the Israel Defence Forces: comparison of some epidemiologic features before and after usage of pre-exposure immune serum globulin prophylaxis. Hepatology. 7:1987;1330-1332.
2. Matzkin H. Epidemiologic features of acute viral hepatitis among the Israel Defence Forces, 1977-1983. J. Infection. 14:1987;271-278.
3. Kark J.D. Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis in army recruits. J. Epidemiol Community Health. 36:1982;176-182.
4. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., Miller W., Shouval D., Wiens B., Calandra G., Ryan J., Provost P., Nalin D. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med. 327:1992;453-457.
5. Lemon S.M., Thomas D.L. Vaccines to prevent viral hepatitis. N. Engl. J. Med. 336:1997;196-204.
6. Nalin D.R., Kuter B.J., Brown L., Patterson C., Calandra G.B., Werzberger A., Shouval D., Ellerbeck E., Block S.L., Bishop R., Wiens B., Skai W.S., Lewis J.A., Sitrin R.D., Provost P.J., Miller W.J., Ryan J.L. Worldwide experience with the CR326F-derived inactivated vaccine in pediatric and adult populations: an overview. J. Hepatol. 18:(Suppl 2):1993;S51-S55.
7. Lerman Y., Shohat T., Ashkenazi S., Almog R., Heering S.L., Shemer J. Efficacy of different doses of immune serum globulin in the prevention of Hepatitis A: a three year prospective study. Clin. Infect. Dis. 17:1993;411-414.
8. Gdalevich M., Grotto I., Mandel Y., Mimouni D., Shemer J., Ashkenazi I. Hepatitis A antibody prevalence among young adults in Israel - the decline continues. Epidemiol and Infect. 121:1998;477-479.
9. Tilzey A.J., Palmer S.J., Barrow S., Perry K.R., Tyrrell H., Safary A., Banatvala J.E. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. Br. Med. J. 304:1992;1272-1276.
10. Jefferson T.O., Behrens R.H., Demicheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine. 12:1994;1379-1383.
11. Jefferson T., Demicheli V., Wright D. An economic evaluation of the introduction of vaccination against hepatitis A in a peacekeeping operation. The case of the United Nations protection force in Yugoslavia. Int. J. Technol. Assess. Health Care. 10:1994;490-497.
12. Poovorawan Y., Theamboonlers A., Chumdermpadetsuk S., Gluck R., Cryz S.J. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine. 13:1995;891-893.
13. Van Doorslaer E., Tormans G., Van Damme P. Cost-effectiveness of vaccination against hepatitis A in travellers. J. Med. Virol. 44:1994;463-469.
14. Behrens R.H., Roberts J.A. Is travel prophylaxis worthwhile? Economic appraisal of prophylactic measures against malaria, hepatitis A and typhoid in travellers. Br. Med. J. 309:1994;918-922.
15. Green M.S., Block C. Apparent effect of immune serum globulin prophylaxis in the military on viral hepatitis incidence in the civilian population in Israel. J. Epidemiol Community Health. 43:1989;187-190.